Literature DB >> 26666824

Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells.

Hongcheng Liu1, Xuefei Hu2, Yuming Zhu2, Gening Jiang2, Sheng Chen3.   

Abstract

Dys-regulation of serine-arginine protein kinase 1 (SRPK1) has been reported in non-small cell lung cancer (NSCLC). However, its functions in the progression of NSCLC remain poorly understood. In this study, the expression of SRPK1 in NSCLC tissues was determined using real-time PCR, and the roles of SRPK1 in the progression of NSCLC were investigated. It was found that both the mRNA level and the protein level of SRPK1 were up-regulated in NSCLC tissues. Forced expression of SRPK1 promoted the growth and migration of NSCLC cells, while knocking down the expression of SRPK1 inhibited the growth, migration, and tumorigenicity of NSCLC cells. Mechanism studies showed that SRPK1 activated the transcriptional activity of beta-catenin/T-cell factor (TCF) complex, and knocking down the expression of SRPK1 attenuated the expression of target genes of beta-catenin/T-cell factor (TCF) complex. In addition, silencing the expression of SRPK1 down-regulated the phosphorylation of GSK3beta. Taken together, SRPK1 might play an oncogenic role in NSCLC, and SRPK1 might be a therapeutic target for NSCLC.

Entities:  

Keywords:  Beta-catenin/TCF signaling; Cell growth and migration; NSCLC; SRPK1

Mesh：

Substances：

Year:  2015        PMID： 26666824     DOI： 10.1007/s13277-015-4510-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  22 in total

1.  The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus.

Authors:  Zhihong Zhou; Jinsong Qiu; Wen Liu; Yu Zhou; Ryan M Plocinik; Hairi Li; Qidong Hu; Gourisanker Ghosh; Joseph A Adams; Michael G Rosenfeld; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2012-06-21       Impact factor: 17.970

2.  SnapShot: Wnt/beta-catenin signaling.

Authors:  Bryan T Macdonald; Mikhail V Semenov; Xi He
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

3.  Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones.

Authors:  Xiang-Yang Zhong; Jian-Hua Ding; Joseph A Adams; Gourisankar Ghosh; Xiang-Dong Fu
Journal:  Genes Dev       Date:  2009-02-15       Impact factor: 11.361

4.  Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells.

Authors:  F Wang; J Zhou; X Xie; J Hu; L Chen; Q Hu; H Guo; C Yu
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

5.  Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling.

Authors:  Yue-Zhen Deng; Ping-Ping Chen; Yan Wang; Dong Yin; H Phillip Koeffler; Baojie Li; Xiang-Jun Tong; Dong Xie
Journal:  J Biol Chem       Date:  2007-10-21       Impact factor: 5.157

6.  Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC.

Authors:  Toru Mukohara; Shinzoh Kudoh; Kuniomi Matsuura; Setsuko Yamauchi; Tatsuo Kimura; Naruo Yoshimura; Hiroshi Kanazawa; Kazuto Hirata; Kiyotoshi Inoue; Hideki Wanibuchi; Shoji Fukushima; Junichi Yoshikawa
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

7.  RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.

Authors:  Zhi-Hong Xu; Jun-Biao Hang; Jia-An Hu; Bei-Li Gao
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

8.  Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways.

Authors:  Dong Xie; Dong Yin; Xiangjun Tong; James O'Kelly; Akio Mori; Carl Miller; Keith Black; Dorina Gui; Johathan W Said; H Phillip Koeffler
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.

Authors:  Bo Zhou; Yandong Li; Qing Deng; Haixiao Wang; Yuping Wang; Bing Cai; Ze-Guang Han
Journal:  Mol Cell Biochem       Date:  2013-05-06       Impact factor: 3.396

10.  Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.

Authors:  M V Gammons; R Lucas; R Dean; S E Coupland; S Oltean; D O Bates
Journal:  Br J Cancer       Date:  2014-07-10       Impact factor: 7.640
View more
  11 in total

1.  CRISPR/Cas9-mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line.

Authors:  Pongphol Prattapong; Chawalit Ngernsombat; Sathid Aimjongjun; Tavan Janvilisri
Journal:  Cancer Rep (Hoboken)       Date:  2019-11-27

2.  Decreased expression of EFCC1 and its prognostic value in lung adenocarcinoma.

Authors:  Liang Xia; Yunke Zhu; Chuanfen Zhang; Senyi Deng; Yulan Deng; Zhenyu Yang; Jiandong Mei; Lunxu Liu
Journal:  Ann Transl Med       Date:  2019-11

3.  Identification of a novel and potent small molecule inhibitor of SRPK1: mechanism of dual inhibition of SRPK1 for the inhibition of cancer progression.

Authors:  Anshuman Chandra; Hanumappa Ananda; Nagendra Singh; Imteyaz Qamar
Journal:  Aging (Albany NY)       Date:  2020-12-03       Impact factor: 5.682

4.  Spatiotemporal expression of regulatory kinases directs the transition from mitosis to cellular morphogenesis in Drosophila.

Authors:  Shuo Yang; Jennifer McAdow; Yingqiu Du; Jennifer Trigg; Paul H Taghert; Aaron N Johnson
Journal:  Nat Commun       Date:  2022-02-09       Impact factor: 17.694

Review 5.  Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis.

Authors:  William P Duggan; Emer O'Connell; Jochen H M Prehn; John P Burke
Journal:  Mol Cell Biochem       Date:  2022-05-18       Impact factor: 3.842

6.  G2/M checkpoint plays a vital role at the early stage of HCC by analysis of key pathways and genes.

Authors:  Li Yin; Cuifang Chang; Cunshuan Xu
Journal:  Oncotarget       Date:  2017-07-18

Review 7.  Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives.

Authors:  Ilias P Nikas; Sophie C Themistocleous; Stavroula A Paschou; Konstantinos I Tsamis; Han Suk Ryu
Journal:  Cells       Date:  2019-12-19       Impact factor: 6.600

8.  Downregulation of SRPK2 promotes cell cycle arrest though E2F1 in non-small cell lung cancer.

Authors:  Xin Li; Shaoyu Yang; Minna Zhang; Shuhuan Xie; Zefeng Xie
Journal:  Eur J Histochem       Date:  2019-12-11       Impact factor: 3.188

9.  Knockdown of Serine-Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells.

Authors:  Xingtao Han; Jinjian Yang; Zhankui Jia; Pengtao Wei; Han Zhang; Wenwei Lv; Jiantao Sun; Qingxiang Huo
Journal:  Oncol Res       Date:  2016-09-22       Impact factor: 5.574

10.  High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival.

Authors:  Hatem Abou-Ouf; Hisham Assem; Sunita Ghosh; R Jeffrey Karnes; Konstantin Stoletov; Nallasivam Palanisamy; John D Lewis; Tarek A Bismar
Journal:  Eur Urol Open Sci       Date:  2020-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.